Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Therapy Concurrent With Radiosensitizing Chemotherapy in Stage T1 Bladder Cancer
NCT00981656Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Nov 2009
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132), fluorouracil and mitomycin c in bladder cancer, sponsored by NRG Oncology. Primary endpoint: Percentage of Participants Free From Radical Cystectomy at 3 years. Started Nov 2009; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)fluorouracilmitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00981656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981656.